Description
Radiglip-M 50 mg + 500 mg is a combination oral medication used to manage type 2 diabetes mellitus in adults. It combines two antidiabetic agents: sitagliptin (50 mg), a DPP-4 inhibitor, and metformin hydrochloride (500 mg), a biguanide. Sitagliptin enhances insulin secretion and reduces glucagon levels in the bloodstream, especially after meals, while metformin decreases hepatic glucose production and improves insulin sensitivity. This dual-action approach helps lower blood sugar levels effectively.
The extended-release formulation allows for once-daily dosing, typically with meals, to improve patient adherence and minimize gastrointestinal side effects associated with metformin. The recommended starting dose for patients not currently on metformin is 50 mg sitagliptin/500 mg metformin twice daily, gradually increased to 50 mg sitagliptin/1000 mg metformin twice daily. For patients already on metformin 850 mg twice daily, the recommended starting dose is 50 mg sitagliptin/1000 mg metformin twice daily. However, dosage adjustments should be individualized based on the patient's current regimen, effectiveness, and tolerability.
This medication is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, or a history of serious hypersensitivity reactions to sitagliptin. It should be used with caution in patients with renal impairment, and dose adjustments may be necessary. Common side effects include gastrointestinal symptoms such as diarrhea, nausea, and abdominal discomfort. Patients should be monitored for signs of lactic acidosis, a rare but serious side effect of metformin. As with all medications, Radiglip-M should be used under the supervision of a healthcare provider.
 10MG.jpeg)
.jpeg)
 2GM.jpeg)
 ..jpeg)
60 MG.jpeg)
 1GM.jpeg)
 25MG.jpeg)
 ..jpeg)
 20MG.jpeg)
Change Language